Last checked at 16 Apr 2015 13:19
Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)
Director's Shareholding
London: Thursday, 16 April 2015: Chi-Med received notification on 16 April 2015 that Simon To, Executive Director and Chairman, has purchased 28,000 ordinary shares of US$1.00 each inChi-Med (the "Shares") at a price of GBP15.85 per share on 15 April 2015.
Following this purchase, Mr To is beneficially interested in 180,000 Shares, representing approximately 0.34% of the current issued share capital of Chi-Med.
Ends
Enquiries
Chi-Med | Telephone: +852 2121 8200 |
Christian Hogg, CEO
|
|
Panmure Gordon (UK) Limited | Telephone: +44 20 7886 2500 |
Richard Gray |
|
Andrew Potts
|
|
Citigate Dewe Rogerson | Telephone: +44 20 7638 9571 |
Anthony Carlisle | Mobile: +44 7973 611 888 |
David Dible | Mobile: +44 7967 566 919 |
About Chi-Med
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.
Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.